Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Nonlinear Dynamics, PSI, Applied Biosystems, CombiMatrix, Polypeptide Laboratories, NeoMPS

PerkinElmer Bundling Geliance with Nonlinear’s Progenesis Software
PerkinElmer will supply Nonlinear Dynamics’ Progenesis SameSpots 2D gel software with its Geliance 1000 Imaging Systems, the companies announced this week. Terms of the agreement were not released.
PerkinElmer released the Geliance platform at the Human Proteome Organization’s annual conference in Seoul in October.

PSI Seeking Comment
The Proteomics Standards Initiative’s document “mzML: Mass Spectrometry Markup Language Specification” is now available for public comment, PSI said this week. The document, available here, is part of HUPO’s PSI’s efforts at standardization in the proteomics field.
PSI is asking for both negative and positive comments. Those who do not want to make their comments public can send them directly to PSI Editor Norman Paton at [email protected].

Applera Declares Dividend for ABI Shareholders
Applera last week said its board declared a regular quarterly dividend of $.0425 for each share of Applera-Applied Biosystems stock. The dividend is payable on Jan. 2, 2008, for shareholders of record as of the close of business day Dec. 3.

CombiMatrix Stock Moves up Nasdaq Tier
CombiMatrix’s stock began trading on the Nasdaq Global Market on Nov. 19. Since splitting from Acacia Research in August [See PM 08/16/07], the company’s stock had been trading on the Nasdaq Capital Market. The Global Market is considered the second of the three tiers making up the Nasdaq exchange and has more stringent listing requirements than the Capital Market tier.

PolyPeptide Buys NeoMPS, Ramps up Capacity
PolyPeptides Laboratories Group said this week it has acquired peptide manufacturer NeoMPS from Isochem for an undisclosed amount.

The acquisition increases PolyPeptide’s manufacturing capacity and capabilities to large-scale peptides from small-scale custom peptides, it said in a statement. As a result of the deal, PolyPeptide now has facilities in Strasbourg, France; San Diego; Torrance, Calif.; Hillerod, Denmark; and Malmo, Sweden.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.